Sample Size The sample size for this study is based on the objective to demonstrate a statistically significant difference in the primary outcome measure (i.e., time to viral eradication). Approximately 350 subjects will be screened with Rapid Pathogens Screening (RPS) Adeno Detector Plus Immunoassay for adenovirus (applied to the conjunctiva of the most involved eye) to allow recruitment of approximately 80 RPS positive subjects in this study, with approximately 40 subjects per treatment group (randomization ratio of 1:1), in anticipation of approximately 40 culture positive subjects per treatment group (assuming a 100% culture positivity rate) and 38 of these culture positive subjects per treatment group completing the study (assuming a 5% dropout rate).